Molecular heterogeneity and receptor co-amplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer

MET inhibition is effective in some MET-amplified esophagogastric cancer (EGC) patients, but understanding acquired and de novo resistance mechanisms will be critical to improving therapy. We identified KRAS mutation as a novel cause of acquired resistance in a patient after a two-year response to M...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Discov
Prif Awduron: Kwak, Eunice L., Ahronian, Leanne G., Siravegna, Giulia, Mussolin, Benedetta, Godfrey, Jason T., Clark, Jeffrey W., Blaszkowsky, Lawrence S., Ryan, David P., Lennerz, Jochen K., Iafrate, A. John, Bardelli, Alberto, Hong, Theodore S., Corcoran, Ryan B.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4670804/
https://ncbi.nlm.nih.gov/pubmed/26432108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-15-0748
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg